Infliximab-induced reactivated Langerhan's cell histiocytosis in a patient with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 9, 2009, Pages 1286-1287

  Rodríguez, Henar Núñez ^a   García, Isidro ^a   Alba, Alberto ^a   Igea, Francisco ^a  

^a HOSPITAL RÍO CARRIÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; AIRWAY OBSTRUCTION; ASTHENIA; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; ENTERITIS; EOSINOPHIL COUNT; EOSINOPHILIC GRANULOMA; FATIGUE; FEMALE; FEVER; GRANULOMATOSIS; HISTIOCYTOSIS X; HUMAN; LETTER; LEUKOCYTE COUNT; MAINTENANCE THERAPY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; TREATMENT DURATION; ULCERATIVE COLITIS; CHEMICALLY INDUCED DISORDER; INTERSTITIAL LUNG DISEASE; PATHOLOGY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 70449717238     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20796     Document Type: Letter

References (7)

1. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997;29:157.
2. Lee-Elliott C, Alexander J, Gould A, et al. Langerhan's cell histiocytosis complicating small bowel Crohn's disease. Gut. 1996;38:296-298. (Pubitemid 26046829)
3. Sutphen JL, Fechner RE. Chronic gastroenteritis in a patient with histiocytosis X. J Pediatr Gastroenterol Nitr. 1986;5:324-328.
4. Geissmann F, Thomas C, Emile JF, et al. Digestive tract involvement in Langerhans cell histiocytosis. The French Langerhans Cell Histiocytosis Study Group. J Pediatr. 1996;129:836.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. (Pubitemid 41770166)
6. Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 1999;94:4195.
7. McClain KL, Kozinetz C. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48:44-49. (Pubitemid 44871592)